Currently, there are no interferon-free treatments available for hepatitis C virus (HCV)-infected patients younger than 12 years. We evaluated the safety and effectiveness of the all-oral regimen ledipasvir-sofosbuvir ± ribavirin in HCV-infected children aged 6 to <12 years. In an open-label study, patients aged 6 to <12 years received ledipasvir 45 mg-sofosbuvir 200 mg as two fixed-dose combination tablets 22.5/100 mg once daily, with or without ribavirin, for 12 or 24 weeks, depending on HCV genotype and cirrhosis status. The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). Twelve patients underwent intensive pharmacokinetic sampling to confirm the appropriateness of the ledipasvir and sofosbuvir dosages. Ninety-two patients were enrolled (88 genotype 1, 2 genotype 3, and 2 genotype 4), with a median age of 9 years (range, 6-11). Most were perinatally infected (97%) and treatment-naive (78%). Two were confirmed to have cirrhosis, while the degree of fibrosis was unknown in 55 patients. The overall SVR12 rate was 99% (91/92; 95% confidence interval, 94%-100%). The single patient not reaching SVR relapsed 4 weeks after completing 12 weeks of treatment. The most common adverse events were headache and pyrexia. One patient had three serious adverse events, which were considered to be not related to study treatment: tooth abscess, abdominal pain, and gastroenteritis. The area under the concentration-time curve and maximum concentration values for sofosbuvir, its primary metabolite GS-331007, and ledipasvir were within predefined pharmacokinetic equivalence boundaries (50%-200%) compared to values in adults in phase 2/3 of the ledipasvir and sofosbuvir studies. Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effective in children 6 to <12 years old with chronic HCV. (Hepatology 2018;68:2158-2166). G lobally, the seroprevalence of hepatitis C virus (HCV) infection in pediatric populations varies, with estimates of 0.05%-0.36% in the United States and Europe to up to 5.8% in regions of Africa.
G lobally, the seroprevalence of hepatitis C virus (HCV) infection in pediatric populations varies, with estimates of 0.05%-0.36% in the United States and Europe to up to 5.8% in regions of Africa. (1, 2) It is estimated that 11 million people under the age of 15 years are HCV antibody-positive, of whom 5 million are viremic. (3) The increasing incidence of HCV infection among young adults, including women of childbearing age, that has been reported since 2011 suggests a potential increase in the number of HCV-infected newborns at risk of developing chronic infection. (4) Most children with chronic HCV are asymptomatic or have mild, nonspecific symptoms; however, despite a lack of symptoms, some children progress to having significant fibrosis or cirrhosis, (5) (6) (7) and a small minority develop hepatocellular carcinoma (8, 9) or end-stage liver disease requiring liver transplantation. (10, 11) In addition, childhood HCV infection has been reported to impact cognitive development and overall health. (12, 13) Currently, treatment with direct-acting antivirals (DAAs) is recommended for all HCV-infected pediatric patients, independent of disease severity, for whom DAAs are approved. (14) In 2017, ledipasvir-sofosbuvir fixed-dose combination and sofosbuvir in combination with ribavirin were approved for use in treatment-naive and interferon-experienced adolescents aged 12 to <18 years old with chronic HCV infection. In addition, in the United States and some other countries, both DAAs have been approved for patients weighing at least 35 kg. (15) (16) (17) (18) For patients younger than 12 years, the only currently approved treatment option is pegylated interferon plus weightbased ribavirin for 24 or 48 weeks, depending on HCV genotype. However, interferon-based therapy is inadequate with regard to both efficacy and safety, with children experiencing poor tolerability and potential impacts on growth and development. (19, 20) We evaluated the safety and effectiveness of ledipasvir 45 mg-sofosbuvir 200 mg for 12 or 24 weeks, with or without ribavirin, in children 6 to <12 years old with HCV genotype 1, 3, or 4 infection.
A subset of patients underwent intensive pharmacokinetic evaluation after 10 days of treatment to determine if exposure to sofosbuvir, its primary metabolite GS-331007, and ledipasvir was similar to that observed in adults.
Patients and Methods

patIeNtS
Eligible patients were 6 to <12 years old and had chronic infection with HCV genotype 1, 3, 4, 5, or 6, with plasma HCV RNA levels ≥10 4 IU/mL. Levels of absolute neutrophils ≥1,500/mm 3 and of hemoglobin ≥11 g/dL were required for female patients and ≥12 g/dL for male patients. Patients could be either treatment-naive or interferon-experienced. Liver biopsy to confirm the presence of cirrhosis was not required.
Patients were excluded from participation if they had any of the following: decompensated liver disease; acute infection with hepatitis A; chronic infection with hepatitis B or human immunodeficiency virus; alpha-fetoprotein level >50 ng/mL; serum creatinine >1.5 mg/dL; estimated glomerular filtration rate <90 mL/minute/1.73 m 2 as calculated by the Schwartz formula; evidence of hepatocellular carcinoma or other malignancy; significant cardiovascular, pulmonary, or neurological disease; daily use of nonsteroidal anti-inflammatory drugs; systemic corticosteroid use for more than 2 weeks (pulmonary/nasal administration was permitted); or psychiatric hospitalization, suicide attempt, or disability resulting from psychiatric illness in the previous 5 years.
Parents or legal guardians provided written informed consent before patients undertook any study-related procedures. Patients who could read and write provided written assent. Assent was obtained in accordance with the requirements of local institutional review boards.
StuDy DeSIgN
This was a phase 2, multicenter, open-label study (ClinicalTrials.gov identifier NCT02249182). All patients received the ledipasvir-sofosbuvir fixed-dose combination tablet of 22.5 mg/100 mg and took two tablets once daily without regard for food for 12 or 24 weeks, with or without ribavirin depending on the HCV genotype and cirrhosis status. Ribavirin was administered twice daily, with dose dependent upon weight ( Table 1 ). The doses of ledipasvir (45 mg) and sofosbuvir (200 mg) were half of those used in adults and were selected based on the pharmacokinetics of sofosbuvir, its major circulating metabolite GS-331007, and ledipasvir in adolescents. (21) All patients were assigned to ledipasvir-sofosbuvir for 12 weeks, except for interferon-experienced patients with cirrhosis and HCV genotype 1, who received ledipasvir-sofosbuvir for 24 weeks. HCV genotype 3 interferon-experienced patients with or without cirrhosis were assigned to ledipasvir-sofosbuvir plus ribavirin for 24 weeks.
The first 12 patients enrolled underwent intensive pharmacokinetic evaluation on the tenth day of treatment to confirm the appropriateness of the ledipasvir-sofosbuvir dose before additional patients were enrolled.
The study protocol was approved by the review board or ethics committee of each institution prior to study initiation. The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki.
eFFICaCy eValuatIoN
Blood samples for determining serum HCV RNA levels were drawn at screening; on day 1 of treatment; at treatment weeks 1, 2, 4, 8, and 12 for all patients and treatment weeks 16, 20, and 24 for those receiving 24 weeks of treatment; and at follow-up weeks 4, 12, and 24. Plasma HCV RNA levels were analyzed using the Roche Ampliprep/COBAS TaqMan HCV Test, v2.0 (Roche Molecular Systems, Inc., Branchburg, NJ), which has a lower limit of quantification (LLOQ) of 15 IU/mL.
The primary efficacy endpoint was the percentage of patients who achieved sustained virologic response (SVR), defined as HCV RNA <LLOQ (15 IU/mL) 12 weeks after stopping the study drugs (SVR12). The SVR12 rate was calculated with a two-sided 95% exact confidence interval (CI) based on the ClopperPearson method. Missing SVR values were imputed as a success if bracketed by values that were termed successes.
SaFety eValuatIoNS
During treatment, vital signs, reported adverse events, concomitant medication intake, and clinical laboratory tests were collected at every visit. Complete physical examinations were conducted on day 1 and at the final treatment visit. During every follow-up visit, vital signs and reported adverse events were collected and symptom-directed physical examinations were done. Concomitant medications were reported at the follow-up week 4 visit, and clinical laboratory tests were done at the week 4 and week 12 follow-up visits. Treatment-emergent clinical and laboratory adverse events were summarized using the Medical Dictionary for Regulatory Activities, version 20.1. At baseline all patients underwent a Tanner pubertal stage assessment. (22, 23) For patients who had achieved Tanner stage 5 at baseline, no further Tanner staging was done. Those who scored below Tanner stage 5 underwent Tanner assessments again at the end of treatment and at follow-up weeks 12 and 24.
At screening up to baseline, tablet swallowability was to be evaluated with placebo to match the 22.5 mg/100 mg tablet.
pHarMaCoKINetIC aNalySeS
For all patients, single plasma samples for pharmacokinetic analysis of sofosbuvir, its metabolite GS-331007, and ledipasvir were collected at the week 1 on-treatment study visit. Additionally, the first 12 patients underwent an intensive pharmacokinetic evaluation and had serial pharmacokinetic blood samples collected on day 10 of treatment to evaluate the pharmacokinetics of sofosbuvir, GS-331007, and ledipasvir in order to confirm the appropriateness of the ledipasvir-sofosbuvir dose before additional patients were enrolled. Patients participating in the intensive pharmacokinetic evaluation had to be HCV treatment-naive, have no evidence of cirrhosis, and weigh 17 to <45 kg. Patients were administered ledipasvir-sofosbuvir along with a standardized meal containing approximately 400 kcal and 13 g of fat.
Following the pharmacokinetic evaluation on day 10, patients continued on the study with no interruption of study drug administration.
Exposure data for sofosbuvir, GS-331007, and ledipasvir from the initial cohort were compared to the integrated adult data from phase 2 and 3 clinical studies using an analysis of variance for log-transformed sofosbuvir, GS-331007, and ledipasvir. The 90% CIs were constructed for the ratio of geometric means of the pharmacokinetic parameters area under the curve (AUC tau ), maximum drug concentration (C max ), and concentration at the end of dosing (C tau ), as appropriate. The equivalence boundaries were set as 50% to 200%.
reSIStaNCe aNalySeS
During treatment and follow-up, plasma samples for viral sequencing were collected at the same time points as for HCV RNA levels. The HCV nonstructural protein 5A (NS5A) and NS5B coding regions were amplified by DDL Diagnostic Laboratory (Rijswijk, The Netherlands) using standard RT-PCR technology at baseline for all patients and at time of virologic failure. The PCR products from baseline samples were deep-sequenced by DDL Diagnostic Laboratory. Reported resistance-associated substitutions (RASs) were present in >15% of the sequence reads.
Results
patIeNt populatIoN
From August 4, 2015, to February 14, 2018, 92 patients were enrolled and followed at 31 study sites in Australia, New Zealand, the United Kingdom, and the United States. The median age was 9 years (range, 6-11), 59% of patients were male, 79% were white, and most were perinatally infected (97%) and treatment-naive (78%) ( Table 2) . Two patients had cirrhosis as confirmed by liver biopsy; the patients were 8 and 11 years old, and both were white and female with genotype 1a infection reported to have been acquired through vertical transmission. Of the remaining 90 patients, 35 were reported as not having cirrhosis, and in 55 patients the degree of fibrosis was unknown. Overall, 96% had genotype 1 (77 genotype 1a, 10 genotype 1b, and 1 genotype 1l), 2% (n = 2) had genotype 4, and 2% (n = 2) had genotype 3.
VIrologIC reSpoNSe
Overall, 99% (91/92; 95% CI, 94%-100%) of patients achieved SVR12 (Table 3) . SVR12 rates were 99% (88/89; 95% CI, 94%-100%) for ledipasvir-sofosbuvir 12 weeks (86/87; 99% in genotype 1 and 2/2, 100% in genotype 4), 100% (1/1 genotype 1; 95% CI, 2.5%-100.0%) for ledipasvir-sofosbuvir 24 weeks, and 100% (2/2 genotype 3; 95% CI, 15.8%-100.0%) for ledipasvir-sofosbuvir plus ribavirin for 24 weeks. The single case who did not achieve SVR12 was an 8-year-old treatment-naive female patient with genotype 1a infection and cirrhosis who received ledipasvir-sofosbuvir for 12 weeks and experienced virologic relapse 4 weeks after treatment.
SaFety
The most commonly reported adverse events were headache (18% of patients), pyrexia (17%) abdominal pain (15%), fatigue (15%), vomiting (15%), and cough (15%) ( Table 4) . No patient discontinued treatment because of an adverse event. All adverse events were mild or moderate in intensity. One patient had three serious adverse events of moderate intensity, all of which were considered by the investigator as unrelated to study treatment: abdominal pain, gastroenteritis, and tooth abscess. Most laboratory abnormalities were mild in severity; 4 patients (4%) had grade 3-4 *Estimated using Schwartz Formula. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; IL-28B, interleukin-28B; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir.
lab abnormalities, 2 of whom had asymptomatic grade 3 amylase elevation with grade 2 or 3 elevations already present at screening. One patient who received ledipasvir-sofosbuvir for 12 weeks had grade 3 hemoglobin level, corresponding to a decrease ≥4.5 g/dL from baseline (18.3 g/dL), with hemoglobin levels ranging from 13.0 to 14.4 g/dL on treatment; and one patient had asymptomatic, transient, and isolated grade 4 neutropenia. Study treatment did not affect pubertal development through 12 weeks of posttreatment follow-up as assessed by Tanner pubertal staging performed by the investigators. Of the 54 male patients enrolled, all had pubic hair and genitalia staging assessment: 94% (51/54) had no change, 4% (2/54) had an increase, and 2% (1/54) were reported to have a reduction in pubic hair staging; 93% (50/54) did not have a change, and 7% (4/54) had an increase in genitalia staging. Among the 38 female patients enrolled, 34 had pubic hair assessment and underwent breast staging: 91% (31/34) had no change and 9% (3/34) had an increase in pubic hair staging; 74% (25/34) had no change, 24% (8/34) had an increase, and 3% (1/34) had a reduction in breast staging, at post-treatment week 12.
Acceptability of the small placebo tablet ledipasvir-sofosbuvir 22.5/100 mg (9 × 4 mm) was evaluated by swallowability assessment of the corresponding placebo tablet in 84 patients and the adult placebo tablet (19 × 10 mm) in 8 patients. All patients were able to swallow the tablets.
pHarMaCoKINetICS
A total of 12 patients were enrolled in the pharmacokinetics lead-in cohort. The median age was 9 years (range, 6-11), and most were white (58%) and male (67%). The median weight of patients in this group was 33 kg (range, 20-41) with a corresponding median weight for age percentile of 64.4% (range, 1.0%-98.6%). The median body mass index was 17 kg/m 2 (range, 14-23) with a corresponding median body mass index for age percentile of 57.7% (range, 1.5%-98.5%). Two patients inadvertently received an adult dose, ledipasvir 90 mg-sofosbuvir 400 mg once daily for 3 days and 17 days, before receiving ledipasvir 45 mg and sofosbuvir 200 mg once daily; pharmacokinetic exposures for the patient who received the adult dose for 17 days were dose-normalized to generate expected exposures for the pediatric dose. Administration of ledipasvir 45 mg and sofosbuvir 200 mg in HCV-infected children provided comparable similar plasma exposures of ledipasvir, sofosbuvir, and GS-331007 to those observed with the adult dose ledipasvir 90 mg-sofosbuvir 400 mg. The AUC tau and C max for ledipasvir, sofosbuvir, and GS-331007 in children aged 6 to <12 years were within the predefined pharmacokinetic equivalence boundaries of 50%-200% when compared with adults from phase 2 and 3 studies (Table 5) .
reSIStaNCe aNalySeS
Deep sequencing for baseline resistance analysis was performed for all 92 patients. With a 15% cutoff, NS5A RASs were detected in 13 patients with genotypes 1 and 4 (14%) and included K24R, L31M, M28T, and Q30H Y93C/H for genotype 1 and L28M for genotype 4. The NS5B nucleotide inhibitor RAS L159F was detected in 3 genotype 1b patients (3%). All patients with baseline NS5A or NS5B nucleotide inhibitor RASs achieved SVR12. The genotype 1a 
Discussion
Sofosbuvir plus ribavirin and ledipasvir-sofosbuvir fixed-dose combination have recently been approved for use in treatment-naive or interferon-experienced patients with chronic HCV who are 12 to <18 years old and, in some countries including the United States, those weighing at least 35 kg. (15) (16) (17) (18) However, for all infected children <12 years of age, the standard of care is still pegylated interferon and weight-based ribavirin. Therefore, there remains a significant unmet medical need for all-oral, interferon-free, DAA regimens for younger children. A recent study conducted in the United States found that only 16% of children born to HCV-infected mothers underwent testing (24) ; this suggests that the estimate of 5 million patients younger than 15 years having chronic viremic infection (3) is likely an underestimation of the true disease burden.
In our study, treatment with ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in children 6 to <12 years old with genotype 1, 3, and 4 HCV infection, with an overall SVR rate of 99%. There was no apparent difference in the prevalence of baseline NS5A RASs in children 6 to <12 compared with adolescents or adults, although the number of younger patients was relatively small. (25, 26) These high rates of SVR were comparable to those observed in adolescents (98%) (19) and adults Abbreviations: LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; ULN, upper limit of normal.
(93%-99%). (27) (28) (29) (30) In addition, both patients with HCV genotype 3 treated with ledipasvir-sofosbuvir plus ribavirin for 24 weeks achieved SVR12. One patient with cirrhosis did not achieve SVR12; currently there are no retreatment options for pediatric patients with DAA experience.
Consistent with observations in adolescents and adults, treatment with ledipasvir-sofosbuvir was well tolerated in children 6 to <12 years old. The most commonly reported adverse events in this study were headache, pyrexia, and abdominal pain. Based on Tanner pubertal staging, treatment with 12 weeks of ledipasvir-sofosbuvir did not affect short-term sexual development.
While this study included mostly HCV genotype 1 patients and only 2 patients with confirmed cirrhosis, the high treatment response and the comparable exposure between children and adults observed in this study suggest the possibility for extrapolation of these results to other HCV genotypes and patients with cirrhosis, who would especially benefit from alternative treatments given the significant toxicities associated with pegylated interferon in this patient population. In summary, ledipasvir 45 mg-sofosbuvir 200 mg once daily with or without ribavirin was highly effective and safe for children 6 to <12 years old with chronic HCV genotype 1, 3, and 4 infection. Given the poor tolerability and the well-documented side effects of pegylated interferon, expanding treatment options for children 6 to <12 with chronic HCV infection to include an all-oral, DAA regimen would represent an important advancement in care in this patient population.
